8-K: Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
8-K: Current report
8-K: Current report
8-K: Current report
8-K: Current report
8-K: Current report
S-3: Registration statement for specified transactions by certain issuers
8-K: Current report
8-K: Current report
8-K: Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
DEFA14A: Others
KemPharm | 8-K: Current report
KemPharm | S-3/A: Registration statement for specified transactions by certain issuers (Amendment)
KemPharm | DEFA14A: Others
KemPharm | DEF 14A: Definitive information statements
KemPharm | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
KemPharm | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
KemPharm | 8-K: Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
KemPharm | 8-K: Current report
KemPharm | 8-K: Current report
No Data